Doximity: AI analysis
$33.34+0.42% today
Doximity sells a sticky doctor network and trades on growth slowing
Doximity makes money from subscriptions, mainly from pharmaceutical manufacturers that want to reach doctors and from healthcare systems that use the platform for communication and virtual care. The case at this price is not that growth is explosive, but that it keeps compounding from a high-margin, software-like base while cash generation stays strong. The risk is that the market already pays for that quality, so any slower growth or heavier share dilution can matter.
The verdict
Earns far more than most companies on the money it uses.
The price asks for about the growth it has delivered.
Some things could go wrong; none look urgent.
Some protection from competitors.
Written by AI on Nov 6, 2026 from company filings and prices to Nov 5, 2026.
Figures as of Nov 5, 2026, the prices this analysis used. The share price is up 0.5% since ($33.34 now); the stock page shows today's figures.
Read the full analysis
Create a free account to read 3 AI analyses a month: the business, its moat, growth, profits, balance sheet, what the price expects, both cases and what to watch. Pro unlocks every analysis.